Compare Home Depot Inc (HD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Home Depot Inc trades at $299 (market cap $293.24B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Home Depot Inc is far larger — about 60.1× Travere Therapeutics Inc. Common Stock's market cap, and Home Depot Inc pays a 3.17% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HD | TVTX | |
|---|---|---|
Market Cap | $293.24B | $4.88B |
Volume | 4,521,013 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $67.52 |
52-Week Low | $281.15 | $26.79 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $353.72B | $5.01B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $293.92, up 1.14% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 33.21% gross margins and 104.3% ROE, though net margins have declined from 10.87% in 2022 to 8.41% currently. Analyst consensus remains bullish with a $379.93 price target, representing 29% upside potential from current levels. Recent institutional activity shows mixed sentiment with both acquisitions and reductions in holdings.
HD faces near-term headwinds from weakening big-ticket demand and margin pressure, but strong Pro business and housing tailwinds support long-term growth. The stock's current valuation at 20.57 P/E appears reasonable relative to historical levels. Key risks include rising mortgage rates impacting housing activity and competitive pressures in home improvement retail.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
